Aastrom makes Dan Orlando interim CEO
This article was originally published in Scrip
Aastrom Biosciences, a developer of patient-specific, expanded multicellular therapies for the treatment of cardiovascular diseases, has appointed Dan Orlando interim CEO. Mr Orlando, who joined Aastrom as chief commercial officer in August, will assume his new role effective 14 December 2012. Aastrom's current president and CEO Tim Mayleben is retiring but will remain on the company's board of directors.